

---

# PHASE ANGLE CLUSTERS IN BIOIMPEDANCE: AN ALTERNATIVE TO BODY MASS INDEX

---

TECHNICAL REPORT

**M<sup>a</sup> Jesús Fuentes Sebio**  
Dra. Fuentes Medical Nutrition Center  
Pontevedra, Spain  
fsebio@cmpont.es

January 2, 2024

## ABSTRACT

**Background:** The “Body Mass Index” (BMI) or “Quetelet Index” is the most widely used tool to diagnose the degree of obesity. Anyone can calculate it, with no other tools than a scale and a measuring rod. However, its accuracy in predicting body fat percentage is low. The aim of this study is to find an alternative to BMI that is more reliable, accessible and easily applicable in daily clinical practice.

**Methods:** Using the K-means method (an unsupervised classification algorithm), we performed a *cluster* analysis of the two phase angles obtained with bioimpedance analysis (BIA) of 641 women with different health status. BMI, age, diseases, treatments and any other data other than the phase angle values of the participants were not taken into account.

**Results:** The *clusters* generated by the K-means algorithm do not coincide with the BMI categories, nor with the predetermined division of individuals into healthy and pathological.

The K-means clustering algorithm identified new patterns that provide information on the greater or lesser predisposition of different individuals to suffer from diseases, taking as a reference their pathological peers in the same *cluster*.

**Conclusions:** The categories generated by the K-means algorithm based on the phase angles obtained by BIA classify individuals according to their health status independently of other variables such as age or BMI.

**Keywords** Body Mass Index (BMI) · Phase Angle · Bioelectrical Impedance Analysis · K-means · *Clusters*

## Contents

<b>1</b>	<b>Introduction</b>	<b>2</b>
<b>2</b>	<b>Objective</b>	<b>3</b>
<b>3</b>	<b>Methodology</b>	<b>3</b>
<b>4</b>	<b>Cluster Analysis</b>	<b>5</b>
<b>5</b>	<b>Discussion</b>	<b>5</b>
<b>6</b>	<b>Conclusion</b>	<b>6</b>

**Bibliography** 7

**Supplementary material** 10

## 1 Introduction

The Belgian astronomer and mathematician Adolphe Quetelet (1796-1874) was ahead of his time in the creation of databases for study and evaluation. One of his best known analyses was the relationship between the weight and height of individuals (what we now call the Body Mass Index or BMI) contained in his book “Sur l’homme” [66]. Based on population statistics, he formulated the aforementioned index also called Quetelet’s index in 1836. His interest in statistics led him to search for mathematical laws that could be adapted to social phenomena, delving into subjects such as education, birth-mortality and even delinquency. What is surprising is that at no time did he suggest that BMI could be applied as a diagnostic value [66]. It was Ancel Keys in 1972 who proposed it to classify people with obesity [14]. It was not the only marker designed to define weight status, although it was the most widely used.

The simplicity of the “Body Mass Index” formula led to its widespread use [6], constituting a very intuitive marker [7] of the level of body fat deposits. Its formula is as follows:

$$\text{BMI} = \frac{\text{Weight (kg)}}{\text{Height}^2(\text{m})}$$

What is striking is that BMI does not reflect the size of the adipose tissue [3] and is incapable of distinguishing changes in the muscle mass, bone and water compartments [5, 15]. This means that we should not be surprised by the report of metabolic disturbances in women with normal BMI with a medium-high percentage of fat [37]. This incongruence was also found in cardiovascular pathologies, in which individuals with low BMI presented greater complications than their counterparts with a higher BMI [38]. Patients with the same diagnosis of heart failure, hypertension or peripheral vasculopathies [8, 10, 9] with low or even normal BMI had worse prognosis than those with higher BMI. Cardiovascular risk, based on the Framingham risk score, is associated with an increase in BMI. What is surprising is that this only predicts 30 % of the cases of the aforementioned risk [4]. This shows that the categories delimited by BMI are not adequate when classifying individuals and even less so when applying them to clinical diagnosis and prognosis.

The optimal BMI range in some medical circles was established between 20-25 kg/m<sup>2</sup>, considering that in this range of values, the risk of mortality is the lowest. However, the risk of diabetes increases from a BMI of 20 kg/m<sup>2</sup>, so relying on such an inaccurate index is a big mistake [40].

BMI does not reflect fat concentration or location. Specifically, **visceral fat**, unlike subcutaneous fat, is found surrounding the internal thoracic and abdominal organs, including the heart [58, 59]. Excess visceral fat is a predisposing factor for inflammatory pathologies, insulin resistance, and dyslipidemia [62, 63]. In 1970, Florey indicated that the BMI, as well as other similar indexes, should not be used to classify individuals according to their degree of adiposity. However, and despite the criticism, the BMI has been widely used in recent years [42, 41].

There are several technologies for calculating body composition: computed tomography (CT), magnetic resonance imaging (MRI), dual X-ray absorptiometry (DXA), hydrometry, ultrasound, isotopic dilution with deuterium or tritium and many others. All of them are limited by their cost, complexity or side effects [47, 48, 49, 51]. On the other hand, bioimpedanciometry (BIA) is the technique that is gaining more and more followers day by day due to its ease of use, safety, low cost and relatively good reliability, although without reaching the effectiveness of other more sophisticated and precise techniques [28, 20].

**Bioimpedance** is an inexpensive and non-invasive technique. It measures the difficulty of the alternating current passing through the different body structures. It is a very useful and practical tool for both clinical and research purposes [20]. It consists of two components: resistance (R) and reactance (Xc) [29]. The resistance is the opposition of body tissues to the flow of electric current. The reactance reflects the dielectric properties of cell membranes, real biological capacitors that generate a delay in the time of electric current circulation [50].

**Phase angle** (PhA) is the most robust parameter of bioimpedance, reflecting cellular integrity and hydration status [52, 53]. It is defined as the geometric angular transformation of the ratio of reactance to resistance and can be calculated with the following formula [21, 22]:

$$\text{Phase angle} = \arctan\left(\frac{\text{Reactance}}{\text{Resistance}}\right) \times \frac{180}{\pi}$$

Any variation in the reactance and resistance values is reflected in the values of the phase angle which represents the duration of the interval from when the electricity passes through the membranes until the voltage changes [43, 44].

Phase angle is a marker of cellular wellness [16, 27]. It is a good reflection of muscle mass and physical activity [18, 19]. High PhA values indicate a good state of health while low values are related to pathologies [32]. Several studies reported a direct relationship between the phase angle and pathologies such as cancer [23], AIDS [22] or other chronic diseases [16, 17]. This makes PhA a powerful tool for monitoring the clinical progression of a given pathology or a change in health status [25].

**Clustering** encompasses a group of unsupervised techniques whose purpose is to create groups or patterns from the data provided. The observations within each group are similar to each other and different from those in the other groups. Unlike supervised machine learning techniques, clustering does not require a training sample because, being an “unsupervised” method, the process ignores the response variable that indicates to which group each observation belongs (if such a variable exists).

Clustering is used in the most diverse and varied fields of science with a variety of applications [36, 2, 26]. The **k-means algorithm** is one of the best known and most widely used clustering techniques [54]. It is fast and easily applicable to large data sets and it is used in machine learning techniques and pattern recognition [60, 61]. It is based on the random search of a set of points called **centroids** (average value of the points of that *cluster*), grouping the different objects in their nearest centroid [55] based on a distance metric which is usually the “Squared Euclidean distance”.

## 2 Objective

The aim of this study is to find a reliable alternative to BMI to classify individuals based on phase angle to predict increased vulnerability to metabolic disease. The aim is to group individuals into new categories with clinical significance.

## 3 Methodology

Observational, retrospective, cross-sectional study including bioimpedanciometric records of 641 white female participants aged 19 to 74 years with a BMI between 17.90 and 56.30 kg/m<sup>2</sup>.

The multi-frequency BIA equipment TANITA MC-980MA with 8 electrodes [56] was the bioimpedance meter at 50 kHz frequency. The measurements were carried out in an upright position with an ambient temperature of 21 °C according to the following requirements:

- No eating or drinking in the last 4 hours.
- No exercise in the last 24 hours.
- Not taking diuretics.
- No alcohol intake in the 8 hours prior to the measurement.

From the data collection, two groups were created with female individuals. One group consists of individuals with no treatments or diseases. The second group comprised women with pathologies such as hyperlipidemia and/or insulin resistance treated (or not) with hypocholesterolemia and/or oral antidiabetics. Individuals with neoplasms, cardiac, hepatic or renal insufficiency as well as persons under treatment with antihypertensives and corticosteroids were excluded<sup>1</sup>. People medicated with levothyroxine, anxiolytics, contraceptives and proton pump inhibitors were not excluded from the study. Table 1 details the number of people with or without treatment as well as the type of treatment.

The **K-means** method, an unsupervised and non-deterministic classification algorithm [45] that groups the data into *k* groups based on the minimum sum of distances between each object and the centroid of its group or *cluster*, is applied to the data set. It is a very agile and versatile algorithm that optimizes the similarities of the data within each *cluster* [46].

Applying the K-means method, four non-overlapping *clusters* of phase angle values were generated, taking into account the minimum sum of distances between the object and the centroid of the *cluster*, as shown in Figures 1 and 2. The number of *clusters* was defined based on the “elbow method”, which calculates the average distance from the centroid to all *cluster* points. That is, it analyzes the percentage of variance explained as a function of the number of *clusters* [64].

---

<sup>1</sup>They produce changes in total body water value.

Table 1: Participant groups and treatments.

Treatments	Number of individuals
None	588
Oral antidiabetics	5
Hypolipidemic agents	23
Oral antidiabetics and hypolipidemic agents	3
Contraceptives and hypocholesterolemic	1
Proton pump inhibitor and hypocholesterolemic	5
Anxiolytics and hypocholesterolemic	10
Levothyroxine and hypocholesterolemic	6




Figure 1: Plots of the four resulting *clusters*.




Figure 2: Different representations of the four *clusters*.

## 4 Cluster Analysis

If we analyze the *clusters* obtained from lowest to highest, we see that number 2 is the one with the lowest phase angles followed by groups 1, 4 and 3. To assess the differences between them, we studied the health conditions as well as the treatments of the pathological individuals in each *cluster*:

- **Cluster 1:** It consists of 209 individuals, 195 of them without health problems and 14 with pathologies, including, in addition to hyperlipidemia and type II diabetes mellitus, multi-organ pathologies and autoimmune diseases that curiously are not found in the other *clusters*. It could be said that this is the **most pathological group** from the metabolic point of view. We see it detailed in Table 2.
- **Cluster 2:** This group is constituted by 74 individuals of which 3 are pathological. It is the *cluster* with the **lowest phase angle** and, curiously, the 3 pathological patients suffer from **muscular pathology**. One of them with chronic elevation of the enzyme Creatinphosphokinase (CPK) and the other 2 suffer from osteomuscular pathology under study. The summary of these 3 pathologic cases can be seen in Table 3.
- **Cluster 3:** It consists of 105 healthy individuals and 17 pathological individuals. This is the group with the **highest phase angle values**. There were no significant pathologies except hyperlipidemia and 3 individuals with type II diabetes, as shown in Table 4.
- **Cluster 4:** This *cluster* is formed by 217 women without pathologies and without treatments, 19 with hyperlipidemia and 2 individuals of this group who suffer from type II diabetes as shown in Table 5.

It is noteworthy that the last two *clusters* (3 and 4) do not present major differences between them in terms of treatment and pathologies. However, *cluster* 3 is the one with the highest phase angle values. To help reveal this difference, the **visceral fat** indices provided by the application of the bioimpedancemeter were compared, taking into account that a good correlation was reported between visceral fat measured by Computed Tomography (CT) and Bioimpedancemetry [57].

As we can see in Table 6, *cluster* 4 is the one with the highest values of visceral fat, which means a greater predisposition to suffer from metabolic pathologies. This means that *cluster* 3 would be the one with the best metabolic health conditions.

According to the above, the k-means *cluster* classification divided the database into 4 groups according to their phase angle. The resulting *clusters* with the most pathological individuals are found in the lower part of the graph where the phase angles are lower. This means that the healthy partners in these *clusters* should be monitored for their potential predisposition to muscle or metabolic diseases. Conversely, individuals with a higher phase angle would be in a more optimal state of health.

If we analyze the BMI (based on the classification of Table 6) of each *cluster*, we can see that in all of them, there are individuals with different BMI values, as we can see in Figure 3. This means that the classification carried out by k-means does not coincide with that of BMI.

## 5 Discussion

The Body Mass Index (BMI) has a long history of use due to its speed and accessibility in diagnosing the degree of obesity. However, it does not achieve the degree of fidelity necessary to discriminate individuals with risk factors associated with an increase in their fat component. The BMI does not reflect the distribution or concentration of adipose tissue, a situation that leads to overlooking individuals with high visceral fat, a highly determinant factor in the development of metabolic pathologies. Thus, individuals with the same BMI but with different fat distribution present disparate clinical manifestations because the increase in energy reserves does not have the same health consequences in subcutaneous adipose tissue as in visceral adipose tissue [33, 34, 35].

Novel techniques are needed to differentiate those individuals with risk factors associated with their increased body mass. BMI does not distinguish between alterations in body composition such as increased muscle mass in athletes or muscle loss in the elderly.

Phase angle is one of the most robust parameters provided by bioimpedance. It reflects the state of hydration and cell mass [27] as well as being a marker of cell well-being [16].

In this research study, a **k-means clustering** of a database of the values of two phase angles obtained by BIA of people with and without metabolic pathologies was performed using the k-means algorithm. No classificatory variables that could distort the investigation were introduced to the algorithm.




Figure 3: Cluster chart according to the BMI classification reflected in Table 7.

The k-means generated four clearly differentiated *clusters* based on the values of their phase angles. Those with the lowest phase angles included individuals with muscle pathology, which raises suspicions about the integrity of the musculoskeletal system of the supposedly healthy individuals in the same category.

The individuals in the next *cluster* do not have such low phase angles, but it could be considered the most complicated, metabolically speaking, since the most pathological individuals are concentrated in this *cluster*.

The last *clusters* (three and four) present similar characteristics although their phase angles are different, so the visceral fat index determined by BIA was used to evaluate the latter, which was found to be higher in the group of individuals with lower phase angles, a situation that predisposes them to the development of metabolic pathologies.

The categories performed by k-means reflect the health status of the individuals, which makes phase angle a powerful predictor of metabolic diseases as well as muscle pathologies.

It would be advisable to extend the study to individuals of other sexes and with different pathologies in order to glimpse clues that will help the clinician when approaching the therapeutic alternatives available. This study has limitations such as the lack of standardization of the different bioimpedance devices available on the market as well as the need to carry out similar studies with larger and more varied samples.

It would be interesting to create several lines of research in different fields of medicine to establish a reference pattern of phase angle values to be applied in daily practice and thus catalog groups of individuals by their predisposition to suffer certain pathologies. Cut-off points that will help us to classify in a first consultation the need or not to delve into diagnostic evaluations.

## 6 Conclusion

The categories generated by the K-means algorithm, based on phase angle values obtained by BIA, classify individuals according to their health status, constituting a much more reliable, non-invasive and relatively simple alternative to BMI for daily clinical practice.



## Bibliography

- [1] Paredes, Jaime González. "Análisis de composición corporal y su uso en la práctica clínica en personas que viven con obesidad." *Revista Médica Clínica Las Condes* 33.6 (2022): 615-622.
- [2] Cervantes, Rodolfo Canas, and Ubaldo Martínez Palacio. "Estimation of obesity levels based on computational intelligence." *Informatics in Medicine Unlocked* 21 (2020): 100472.
- [3] Romero-Corral, Abel, et al. "Accuracy of body mass index in diagnosing obesity in the adult general population." *International journal of obesity* 32.6 (2008): 959-966.
- [4] González, Susana Ruíz, et al. "Sensitivity and specificity of body mass index and main risk factors for cardiovascular disease in middle-income urban participants in Guanajuato, Mexico." *Nutrición hospitalaria: Organo oficial de la Sociedad española de nutrición parenteral y enteral* 39.5 (2022): 1027-1036.
- [5] del Castillo, José Miguel Soriano, Paola Sechi, and Pietro Marco Boselli. "BMI-BFMNU: A structural index linked to fat mass." *Revista Española de Nutrición Humana y Dietética* 25.1 (2021): 104-110.
- [6] Whelan, Kevin. *Advanced nutrition and dietetics in obesity*. John Wiley and Sons, 2018.
- [7] Ceccarelli, Gabriele, et al. "BMI and inverted BMI as predictors of fat mass in young people: A comparison across the ages." *Annals of Human Biology* 47.3 (2020): 237-243.
- [8] Lavie, Carl J., Richard V. Milani, and Hector O. Ventura. "Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss." *Journal of the American college of cardiology* 53.21 (2009): 1925-1932.
- [9] Lavie, Carl J., et al. "Obesity and cardiovascular diseases: implications regarding fitness, fatness, and severity in the obesity paradox." *Journal of the American College of Cardiology* 63.14 (2014): 1345-1354.
- [10] Lavie, C. J. et al. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. *JACC Heart Fail.* 1, 93–102 (2013).
- [11] Frankenfield, David C., et al. "Limits of body mass index to detect obesity and predict body composition." *Nutrition* 17.1 (2001): 26-30.
- [12] Nyholm, Maria, et al. "The validity of obesity based on self-reported weight and height: implications for population studies." *Obesity* 15.1 (2007): 197-197.
- [13] Quetelet, M. A. *A Treatise on Man and the Development of His Faculties: Sur L'homme, Et Le Développement de Ses Facultés... Now First Transl. Into English*. B. Franklin, 1968.
- [14] Keys, Ancel, et al. "Indices of relative weight and obesity." *Journal of chronic diseases* 25.6-7 (1972): 329-343.
- [15] Xia, Jonathan Y., Donald M. Lloyd-Jones, and Sadiya S. Khan. "Association of body mass index with mortality in cardiovascular disease: new insights into the obesity paradox from multiple perspectives." *Trends in cardiovascular medicine* 29.4 (2019): 220-225.
- [16] K. Norman, N. Stobäus, M. Pirlich, and A. Bösby-Westphal, "Bioelectrical phase angle and impedance vector analysis - clinical relevance and applicability of impedance parameters," *Clinical Nutrition*, vol. 31, no. 6, pp. 854–861, 2012.
- [17] De Blasio, F., et al. "Raw BIA variables are predictors of muscle strength in patients with chronic obstructive pulmonary disease." *European Journal of Clinical Nutrition* 71.11 (2017): 1336-1340.
- [18] Boksem, E., et al. "Prediction of total body electrical resistance normal values based on limb muscle thickness assessed by ultrasound." *European Journal of Clinical Nutrition* 75.8 (2021): 1267-1274.
- [19] Primo, David, et al. "Correlation of the phase angle with muscle ultrasound and quality of life in obese females." *Disease Markers* 2022 (2022).
- [20] Jackson, A. A., et al. "Body composition assessment in nutrition research: value of BIA technology." *European journal of clinical nutrition* 67.1 (2013): S71-S78.
- [21] Mattar, J.A. Application of total body bioimpedance to the critically ill patient. *Brazilian Group for Bioimpedance Study. New Horiz.* 1996, 4, 493–503.
- [22] Schwenk, Achim, et al. "Phase angle from bioelectrical impedance analysis remains an independent predictive marker in HIV-infected patients in the era of highly active antiretroviral treatment." *The American journal of clinical nutrition* 72.2 (2000): 496-501.
- [23] Toso, Silvia, et al. "Altered tissue electric properties in lung cancer patients as detected by bioelectric impedance vector analysis." *Nutrition* 16.2 (2000): 120-124.

- [24] Oliveira, Rafael, et al. "Comparisons between bioelectrical impedance variables, functional tests and blood markers based on BMI in older women and their association with phase angle." *International Journal of Environmental Research and Public Health* 19.11 (2022): 6851.
- [25] Barbosa-Silva, Maria Cristina G., et al. "Bioelectrical impedance analysis: population reference values for phase angle by age and sex—." *The American journal of clinical nutrition* 82.1 (2005): 49-52.
- [26] Thongprayoon, Charat, et al. "Machine learning consensus clustering of morbidly obese kidney transplant recipients in the united states." *Journal of Clinical Medicine* 11.12 (2022): 3288.
- [27] Kyle, Ursula G., et al. "Bioelectrical impedance analysis—part I: review of principles and methods." *Clinical nutrition* 23.5 (2004): 1226-1243.
- [28] Kyle, Ursula G., et al. "Bioelectrical impedance analysis—part II: utilization in clinical practice." *Clinical nutrition* 23.6 (2004): 1430-1453.
- [29] Lukaski, Henry C., et al. "Classification of hydration in clinical conditions: indirect and direct approaches using bioimpedance." *Nutrients* 11.4 (2019): 809.
- [30] Carlson-Newberry, Sydne J., and Rebecca B. Costello. "Project Overview and Committee Summary." *Emerging Technologies for Nutrition Research: Potential for Assessing Military Performance Capability*. National Academies Press (US), 1997.
- [31] Wilhelm-Leen, Emilee R., et al. "Phase angle, frailty and mortality in older adults." *Journal of general internal medicine* 29 (2014): 147-154.
- [32] Canello, Raffaella, et al. "Phase angle (PhA) in overweight and obesity: evidence of applicability from diagnosis to weight changes in obesity treatment." *Reviews in Endocrine and Metabolic Disorders* 24.3 (2023): 451-464.
- [33] Mazurek, Tomasz, et al. "Human epicardial adipose tissue is a source of inflammatory mediators." *Circulation* 108.20 (2003): 2460-2466.
- [34] Iacobellis, Gianluca. "Local and systemic effects of the multifaceted epicardial adipose tissue depot." *Nature Reviews Endocrinology* 11.6 (2015): 363-371.
- [35] Ouchi, Noriyuki, et al. "Adipokines in inflammation and metabolic disease." *Nature reviews immunology* 11.2 (2011): 85-97.
- [36] Hennig, Christian, et al., eds. *Handbook of cluster analysis*. CRC press, 2015.
- [37] Romero-Corral, Abel, et al. "Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality." *European heart journal* 31.6 (2010): 737-746.
- [38] Pocock SJ, Ariti CA, McMurray JJV, et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. *Eur Heart J* 2013;34(19):1404–13.
- [39] Clinton, Steven K., Edward L. Giovannucci, and Stephen D. Hursting. "The world cancer research fund/American institute for cancer research third expert report on diet, nutrition, physical activity, and cancer: impact and future directions." *The Journal of nutrition* 150.4 (2020): 663-671.
- [40] Armstrong, Sarah, Arianne N. Sweeting, and John PH Wilding. *Clinical obesity in adults and children*. Eds. Peter G. Kopelman, Ian D. Caterson, and William H. Dietz. Blackwell, 2005.
- [41] Gard, Michael, Darren Powell, and José Tenorio, eds. *Routledge handbook of critical obesity studies*. Routledge, 2021.
- [42] Florey, Charles du V. "The use and interpretation of ponderal index and other weight-height ratios in epidemiological studies." *Journal of chronic diseases* 23.2 (1970): 93-103.
- [43] Lima, Júlia, et al. "Prognostic value of phase angle and bioelectrical impedance vector in critically ill patients: A systematic review and meta-analysis of observational studies." *Clinical Nutrition* 41.12 (2022): 2801-2816.
- [44] de Borba, Evandro Lucas, et al. "Phase angle of bioimpedance at 50 kHz is associated with cardiovascular diseases: systematic review and meta-analysis." *European Journal of Clinical Nutrition* 76.10 (2022): 1366-1373.
- [45] Tripathi, Atul. *Practical machine learning cookbook*. Packt Publishing Ltd, 2017.
- [46] Lewis, N. D. *Machine Learning Made Easy With R*. ND Lewis, 2017.
- [47] Day, Kaitlin, et al. "Comparison of a bioelectrical impedance device against the reference method dual energy X-ray absorptiometry and anthropometry for the evaluation of body composition in adults." *Nutrients* 10.10 (2018): 1469.



- [48] Ng, Bennett K., et al. "Validation of rapid 4-component body composition assessment with the use of dual-energy X-ray absorptiometry and bioelectrical impedance analysis." *The American journal of clinical nutrition* 108.4 (2018): 708-715.
- [49] García Almeida, José Manuel, et al. "Nuevo enfoque de la nutrición. Valoración del estado nutricional del paciente: función y composición corporal." *Nutrición Hospitalaria* 35.SPE3 (2018): 1-14.
- [50] Carreira, José, et al. "Aplicaciones del ángulo de fase de la bioimpedancia en la nutrición clínica." (2022).
- [51] Moreira, Osvaldo Costa, et al. "Métodos de evaluación de la composición corporal: una revisión actualizada de descripción, aplicación, ventajas y desventajas." *Arch Med del Deport* 32.6 (2015): 387-94.
- [52] Xiong, Zi-Hong, et al. "The use of bioelectrical impedance analysis measures for predicting clinical outcomes in critically ill children." *Frontiers in Nutrition* 9 (2022): 847480.
- [53] Zdolsek, Hans Joachim, Olof Anton Lindahl, and Folke Sjöberg. "Non-invasive assessment of fluid volume status in the interstitium after haemodialysis." *Physiological measurement* 21.2 (2000): 211.
- [54] Hartigan, John A., and Manchek A. Wong. "Algorithm AS 136: A k-means clustering algorithm." *Journal of the royal statistical society. series c (applied statistics)* 28.1 (1979): 100-108.
- [55] Simovici, Dan A. *Clustering: Theoretical and Practical Aspects*. World Scientific, 2021.
- [56] Jiang, Fanglin, et al. "Accuracy of estimated bioimpedance parameters with octapolar segmental bioimpedance analysis." *Sensors* 22.7 (2022): 2681.
- [57] Omura-Ohata, Yoko, et al. "Efficacy of visceral fat estimation by dual bioelectrical impedance analysis in detecting cardiovascular risk factors in patients with type 2 diabetes." *Cardiovascular diabetology* 18.1 (2019): 1-8.
- [58] Bertaso, Angela Gallina, et al. "Gordura epicárdica: definição, medidas e revisão sistemática dos principais desfechos." *Arquivos Brasileiros de Cardiologia* 101 (2013): e18-e28.
- [59] Frank, Aaron P., et al. "Determinants of body fat distribution in humans may provide insight about obesity-related health risks." *Journal of lipid research* 60.10 (2019): 1710-1719.
- [60] Mitchell, Tom M. "Machine learning." (1997).
- [61] Duda, R. O., P. E. Hart, and D. G. Stork. "Pattern Classification 2nd Edition: A Wiley-Interscience Publication." (2000).
- [62] Després, Jean-Pierre. "Body fat distribution and risk of cardiovascular disease: an update." *Circulation* 126.10 (2012): 1301-1313.
- [63] Tchernof, Andre, and Jean-Pierre Després. "Pathophysiology of human visceral obesity: an update." *Physiological reviews* (2013).
- [64] Bholowalia, Purnima, and Arvind Kumar. "EBK-means: A clustering technique based on elbow method and k-means in WSN." *International Journal of Computer Applications* 105.9 (2014).
- [65] Martínez-Hortelano, Jose Alberto, et al. "Monitoring gestational weight gain and prepregnancy BMI using the 2009 IOM guidelines in the global population: a systematic review and meta-analysis." *BMC pregnancy and childbirth* 20 (2020): 1-12.
- [66] QUÉTELET, Adolphe. *Sur l'homme et le développement de ses facultés [On man and the development of his faculties]*. Paris: Bachelier, 1835.

## Supplementary material

Table 2: *Cluster 1.*

<b>N°</b>	<b>Medication</b>	<b>Pathologies</b>
1	Simvastatin and anxiolytics drugs	Hyperlipidemia
2	Simvastatin, Insulin and oral hypoglycemic agents	Pluripathological
3	Metformin	Polycystic ovarian disease
4	Atorvastatin	Hyperlipidemia and intestinal pathology
5	Simvastatin and anxiolytics drugs	Hyperlipidemia and untreated rheumatoid arthritis
6	Hypolipidemic agents and Levothyroxine	Hyperlipidemia and hypothyroidism
7	Metformin	Type II Diabetes and autoimmune pathology
8	Hypolipidemic agents	Hyperlipidemia and liver disease
9	Simvastatin and anxiolytics drugs	Hyperlipidemia and total hysterectomy
10	Simvastatin	Hyperlipidemia, renal pathology and polycystic ovarian
11	Atorvastatin and Levothyroxine	Hyperlipidemia and hypothyroidism
12	Simvastatin and Levothyroxine	Hyperlipidemia and hypothyroidism
13	Simvastatin and oral Contraceptive	Hyperlipidemia and polycystic ovarian
14	Atorvastatin	Hyperlipidemia

Table 3: *Cluster 2.*

<b>N°</b>	<b>Medication</b>	<b>Pathologies</b>
1	Metformin	Elevated CPK muscle enzyme y polycystic ovarian
2	Simvastatin	Hyperlipidemia and muscular pathology
3	Rosuvastatin	Hyperlipidemia and muscular pathology

Table 4: *Cluster 3.*

<b>N°</b>	<b>Medication</b>	<b>Pathologies</b>
1	Simvastatin	Hyperlipidemia
2	Rosuvastatin	Hyperlipidemia e hysterectomy
3	Insulin and oral antidiabetics	Type II Diabetes
4	Oral antidiabetics	Type II Diabetes
5	Simvastatin and Ezetimide	Hyperlipidemia
6	Simvastatin	Hyperlipidemia
7	Simvastatin	Hyperlipidemia
8	Simvastatin	Hyperlipidemia
9	Simvastatin and anxiolytics drugs	Hyperlipidemia
10	Metformin	Type II Diabetes and hysterectomy
11	Simvastatin and Gemfibrocil	Hyperlipidemia
12	Simvastatin and Anxiolytics drugs	Hyperlipidemia
13	Pitavastatin	Hyperlipidemia and polycystic ovarian
14	Simvastatin and Levothyroxine	Hyperlipidemia
15	Simvastatin and anxiolytics drugs	Hyperlipidemia
16	Rosuvastatin and anxiolytics drugs	Hyperlipidemia
17	Simvastatin	Hyperlipidemia

Table 5: *Cluster 4.*

Nº	Medication	Pathologies
1	Pravastatin and anxiolytics drugs	Hyperlipidemia
2	Atorvastatin and Lansoprazole	Hyperlipidemia
3	Rosuvastatin and Omeprazole	Hyperlipidemia
4	Pitavastatin	Hyperlipidemia
5	Fenofibrate and Levothyroxine	Hyperlipidemia
6	Simvastatin and Metformin	Hyperlipidemia and Type II Diabetes
7	Simvastatin	Hyperlipidemia
8	Simvastatin	Hyperlipidemia
9	Atorvastatin	Hyperlipidemia
10	Simvastatin and anxiolytics drugs	Hyperlipidemia
11	Atorvastatin and anxiolytics drugs	Hyperlipidemia
12	Atorvastatin and anxiolytics drugs	Hyperlipidemia
13	Atorvastatin	Hyperlipidemia
14	Metformin and anxiolytics drugs	Type II Diabetes
15	Atorvastatin	Hyperlipidemia
16	Atorvastatin	Hyperlipidemia
17	Atorvastatin	Hyperlipidemia
18	Atorvastatin and Levothyroxine	Hyperlipidemia
19	Atorvastatin	Hiperlipidemia

Table 6: *Cluster 3 and 4 visceral fat index analysis.*

<i>Cluster</i>	<i>Mean</i>	<i>Standard deviation</i>
3	7.098	3.269
4	7.275	3.139

Table 7: BMI classification [65].

<b>BMI</b>	<b>Weight status</b>
<18.5	Underweigh
18.5 - 24.9	Normal
25.0 - 29.9	Preobesity
≥30.0	Obese
30.0 - 34.9	Obese class I
35.0 - 39.9	Obese class II
≥40	Obese class III